BioLight Israeli Life Sciences Investments Ltd. (BLGTY:

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioLight Israeli Life Sciences Investments Ltd. (BLGTY: OTCQX International) | BioLight Announces U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert for the Treatment of Glaucoma BioLight Announces U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert for the Treatment of Glaucoma

BioLight Announces U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert for the Treatment of Glaucoma

PR Newswire

TEL-AVIV, Israel , May 14, 2014 /PRNewswire/ --

BioLight Israeli Life Sciences Investments Ltd.   (TASE: BOLT) ( OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has been informed that a patent number 8,722,739 covering the proprietary formulation of Latanoprost, the medication contained in its controlled release insert for the treatment of Glaucoma, has been granted by the U.S. Patent and Trademark Office. The patent is intended to protect, inter alia, the chemical structure of the active ingredient for the treatment of glaucoma. The patent is also covering the release of the active ingredient from the Eye-D® subconjunctival insert and its use in treating elevated intra-ocular pressure in patients with glaucoma and ocular hypertension. The patent and its registration will be in effect at least until April 2030 .

ViSci holds an exclusive option from Novaer LLC to a worldwide exclusive license for any use of the insert's proprietary technology. Use of such insert is an effective therapeutic solution to the well-known poor compliance rates with chronic eye-drop administration in ophthalmology.

Recently ViSci has successfully completed an ocular toxicology and safety study in animals and has filed an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its Eye-D® Latanoprost controlled release insert for the treatment of glaucoma. The study will be conducted at up to seven investigative sites in the U.S.A.

Suzana Nahum-Zilberberg , BioLight's chief executive officer said, "We believe that our Eye-D® controlled-release insert will provide an effective solution to the well-known poor compliance with chronic eye-drop administration commonly used today as a treatment for glaucoma. This U.S. patent approval will strengthen our business, marketing and competitive advantages of our company."

About Glaucoma:  

Glaucoma, which created pressure within the eye causes damage to the optic nerve that may lead to full or partial blindness, is considered the second most common cause of blindness worldwide. According to estimates commonly accepted in the field, there are now about 67 million people worldwide that suffer from the disease. Glaucoma is usually a chronic disease requiring lifelong treatment, and based on assessments, the global market for drug therapy and surgery, is estimated at $4 billion annually.

About BioLight  

BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped into "clusters" around defined medical conditions. Its two current clusters are in ophthalmology via 100% ownership of XLVision Sciences and in cancer diagnostics via a 29% controlling ownership of Micromedic (TASE: MCTC). XLVision technologies include IOPtiMate™, a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D™, a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designed to detect colorectal, cervical, breast, bladder, lung and other cancers. Leading key investors, holding about 45% of BioLight's shares, are Mr. Israel Makov , Chairman of Sun Pharmaceuticals and former CEO and President of Teva Pharmaceuticals, with Mr. Dilip Shanghvi , founder of Sun Pharmaceuticals, India's largest pharmaceutical company, and Mr. Dan Oren , founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel .

For more information please visit the Company's website at http://www.bio-light.co.il .

 

CONTACTS:

BioLight
Itai Bar-Natan , CFO ( itai@bio-light.co.il )
Tel: +972-73-2753400

LHA
Kim Sutton Golodetz ( kgolodetz@lhai.com )
+1-212-838-3777
Or
Bruce Voss ( bvoss@lhai.com )
+1-310-691-7100


SOURCE BioLight Israeli Life Sciences Investments Ltd.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading